Abstract:
Monozygotic twin sisters, with non-hematological symptoms of Fanconi anemia (FA), were discovered to be somatic mosaics for mutations in the FANCA gene. Skin fibroblasts, but not lymphocytes or committed hematopoietic progenitors, were sensitive to DNA cross-linking agents. Molecular analysis revealed, in skin cells of both twins, a frameshift causing deletion in exon 27 (2555ΔT) and an exon 28 missense mutation (2670G>A / R880Q). The latter resulted in primarily cytoplasmic expression and reduced function of the mutant FANCA (R880Q) protein. Surprisingly, the same acquired exon 30 missense change (2927G>A / E966K) was detected in the hematopoietic cells of both sisters, but not in their fibroblasts, nor in either parent. This compensatory mutation existed in cis with the maternal exon 28 mutation, and it restored function and nuclear localization of the resulting protein. Both sisters have been free of hematological symptoms for over two decades, suggesting that this de novo mutation occurred prenatally in a single hematopoietic stem cell (HSC) in one twin, and that descendants of this functionally corrected HSC, via intra-uterine circulation, repopulated the blood lineages of both sisters. This finding suggests that treating FA patients with gene therapy might require transduction of only a few hematopoietic stem cells.
Introduction:
Fanconi anemia (FA; OMIM #227650) 1 is a heterogeneous recessive genetic disorder, with clinical symptoms including bone marrow failure, multiple birth defects and cancer predisposition [2] [3] [4] . Currently, there are 12 known complementation groups (A, B, C, D1, D2, E, F, G, I, J, L, and M) [5] [6] [7] [8] . The diagnostic hallmark of Fanconi anemia is hypersensitivity to DNA crosslinking agents such as diepoxybutane (DEB) or mitomycin C (MMC) 9, 10 . About 25% of Fanconi anemia patients 11 have somatic mosaicism in their hematopoietic system, which contains clastogen sensitive mutant cells as well as crosslinker resistant, revertant cells. Multiple molecular mechanisms for restoration of normal function in mutant FA alleles have been demonstrated, including compensatory mutations in cis, intragenic crossovers or gene conversion [11] [12] [13] [14] . Reversion is thought to occur in a single hematopoietic progenitor, followed by selection and growth expansion of the cells with a functional FA allele. Clinically, somatic mosaicism for functionally corrected hematopoietic cells could prevent the onset of anemia, at least temporarily. Indeed, in murine models of FA, selection of functionally corrected hematopoietic cells has been clearly demonstrated [15] [16] [17] .
Clinical case reports of somatic mosaicism have involved reversions in the FANCA, FANCC and FANCD2 genes and have demonstrated correction of multiple blood lineages, suggesting growth selection of corrected progenitors [11] [12] [13] [14] 18 . Some of the patients had milder than expected hematological symptoms. However, to date somatic mosaicism caused by functional reversion at the level of the hematopoietic stem cell (HSC) and oligoclonal repopulation by unassisted natural selection has yet to be demonstrated. Here we provide evidence that molecular reversion can occur at the level of the HSC and result in long-term restoration of hematopoiesis. We describe the molecular events in monozygotic twin sisters 19 who have mutations in the FANCA gene but, at age 28, are free of any hematological signs or symptoms.
only.
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Materials and methods:

Cell lines and patient samples
The FANCA functionally-null GM6914 cell line has been previously described 20 
Cytogenetic analysis
Cytogenetic analysis of mitomycin C (MMC; Sigma-Aldrich) and diepoxybutane (DEB;
Sigma-Aldrich) sensitivity, by chromosomal breakage (DEB) and radial formation (MMC) assays, was performed as previously reported [22] [23] [24] [25] . At least 35 G-banded metaphase cells from each culture were scored for DNA breaks and radial formations by microscopic analysis. For complementation analysis, primary PD839 fibroblasts (PD839.F) were infected with retroviral supernatant representing various FA genes (A, C, D2, F, and G) as previously described 26 . Karyotyping of bone marrow was done according to standard procedures, similar to those previously described 24 .
Mutation confirmation in genomic DNA
Mutations discovered by sequencing were confirmed in genomic DNA, obtained as previously described, 27 using allele-specific restriction enzyme digests of PCR products generated using the following cycling conditions and standard buffers: 95°C for 5 min., followed by 37 cycles of 95°C for 30 sec., X°C for 30 sec., and 72°C for 30 sec., followed by 72°C for 1 min. X = 51°C for exon 27 assay, 54°C for exon 28 assay, and 52°C for exon 30 assay.
Exon 27 assay for the 2555ΔT mutation:
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Constitutive expression constructs
The retroviral expression vectors pMMP-puro 26 and pMMPpuroFANCA 28 were described previously, and include an IRES driven Puromycin resistance cassette 28 .
To obtain retroviral vectors for the constitutive expression of patient-derived, variant FANCA alleles, RNA was extracted from cells as previously described 29 . RT-PCR products, produced with primers 5' AATGAGGATGACAGCAGCG 3', and 5' GACAGACGAAGGCAGGCG 3', were used to replace the Bpu1102 I to BamH I fragments in pMMPpuroFANCA. The PCR cycling program for this was 95°C for 5 min., followed by 40 cycles of 95°C for 30 sec., 58°C for 30 sec., and 72°C for 2 min., followed by 72°C for 10 minutes. In addition, site-directed mutagenesis was performed on the pMMPpuroFANCA construct to produce the R880Q, E966K, and R880Q-E966K
(double) mutant FANCA cDNAs with the QuikChange site-directed mutagenesis kit (Stratagene). The cDNA inserts were verified by direct DNA sequencing. Production of retroviral supernatants from pMMP-based contructs, and infection of fibroblasts, were performed as previously described 30, 31 . The resulting cell lines were cultured under 1 μg/ml Puromycin selection.
Immunoblotting for FANCA in patient cell lines
Immunoblotting was performed as previously described 21 using N-terminal anti-FANCA antibody 32 . For controls, primary cells were infected with wild type FANCA retrovirus as previously described 30, 31 .
Immunofluorescence microscopy
Cells were fixed with 2% paraformaldehyde in phosphate-buffered saline (PBS) for 20 minutes, followed by permeabilization with 0.2% Triton X-100 in PBS (3 minutes).
They were then incubated in anti-FANCA (N terminal) antibody 32 , diluted 1:200 in 3%
bovine serum albumin/0.05% Triton X-100/0.04% sodium azide/PBS, for 1 hour at room temperature. Cells were subsequently washed 3 times in PBS, then incubated in fluorescein-conjugated anti-rabbit IgG secondary antibody (Jackson Immunoresearch, West Grove, PA), diluted 1:500 in 3% bovine serum albumin/0.05% Triton X-100/0.04% sodium azide/PBS, for 30 minutes at room temperature. Three more washes were applied, and the nuclei were counterstained with DAPI (4,6 diamidino-2-phenylindole) diluted in PBS at 1 µg/mL for 5 minutes. Three more washes were applied, and the slides were mounted in Vectashield (Vector Laboratories, Burlingame, CA). Images were captured on a Nikon Zeiss Axioplan 2 microscope (Tokyo, Japan) using a 40X objective oilimmersion lens, mounted CCD camera, and OpenLab (Improvision) software. Images were trimmed and the overall brightness and contrast adjusted using Adobe Photoshop software (Adobe, San Jose, CA).
Conditional expression constructs
The FA-A cell line GM6914 was transfected with plasmid pREV-Tet-Off (BDBiosciences, catalog# 6140-1), and stable integrants were selected with G418. Lysates from individual clones were analyzed by PVDF membrane Western blot using the anti-VP16(1-21) monoclonal IgG 1 antibody (Santa Cruz Biotech; catalog # sc-7545), diluted 1:1000 in 1% milk in PBS, overnight at 4°C. An anti-mouse IgG 1 HRP conjugated secondary antibody (Santa Cruz; catalog # sc-2969), was used at 1:3000 dilution in 1% milk in PBS. The three pREV-Tet-Off transfected GM6914 clones demonstrating the highest levels of tTA expression were retained. Next, the patient derived variant FANCA cDNAs were inserted into plasmid pREV-TRE (BD-Biosciences, catalog# 6137-1).
Retroviral supernatants were produced from the various resulting constructs using the packaging cell line PA317 33 . The recombinant vectors containing the wild type, paternal, maternal, or lymphoblast allele of FANCA were individually used to infect the three selected clones, as previously described 30, 31 , to produce a set of 4 cell lines for each clone. Resulting cell lines were placed under 250μg/ml Hygromycin B and 400μg/ml were cultured for between 5 to 7 days and then were analyzed using the CyQUANT assay and FLUOstar reader as described above.
CFU-GM and BFU-E. Low-density bone marrow cells were obtained as previously described 36 , except for the use of the EasySep kit (Stem Cell Technologies, Vancouver, B.C.). These cells were exposed to various doses of Mitomycin C in suspension culture for only 24 hours, after which they were washed in complete medium and plated in methylcellulose with complete medium, Steel factor (50 ng/ml), IL-3 (10 ng/ml), and erythropoietin (2 Units/ml). Colony forming units granulocyte-macrophage (CFU-GM) and burst forming units erythrocyte (BFU-E) were counted 14 days after plating.
Multilineage progenitor assays
Multilineage progenitor assays were undertaken as previously described 14 ; DNA obtained from individually plucked CFU-GM and BFU-E from both twins was analyzed via the abovementioned PCR-digest assay for the acquired exon 30 sequence change (2927G>A).
X-inactivation assay
An X chromosome inactivation assay was applied to genomic DNA from patients' whole blood and fibroblasts, as well as to DNA from the mother, from one male control, and from one female control. The assay was performed essentially as previously described 37 .
DNA samples were digested with Hpa II prior to PCR.
Results:
Clinical description of patients
The patients were previously described monozygotic twin sisters 19 , with normal complete blood counts and differential counts from initial diagnosis at age 6 months through follow-up at age 13. One twin had initially elevated chromosome breakage in DEB treated peripheral blood lymphocytes (PBLs), which resolved by age 13, while the other twin demonstrated normal breakage even at six months. Both twins exhibit short stature and thumb defects, and one has abdominal skin hyperpigmentation and had surgically corrected malformed kidneys. The twins are currently 28 years old and remain free of hematological signs and symptoms. Their complete blood counts are normal, the only.
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Determination of complementation group and mutation detection
Fibroblasts from one twin (proband) were cytogenetically analyzed for chromosome radial formation with mitomycin C (MMC) and diepoxybutane (DEB) treatment and were found to be fully sensitive to both agents (Table 1A) . However, lymphocytes from the same twin were found to be MMC resistant (Table 1A ). The MMC sensitivity of fibroblasts was corrected with a FANCA retrovirus (Table 1B) . Exon by exon sequencing of FANCA from genomic DNA revealed sequence changes as follows, with numbering referring to NCBI nucleotide database entry #NM_000135; the start codon is at position 32. A single thymidine was deleted at position 2555 (2555ΔT) in exon 27, leading to a frameshift and resulting premature termination codon in exon 28. In exon 28, a nucleotide change of 2670G>A, resulting in an arginine to glutamine missense change at amino acid 880 (R880Q), was found. Both the previously described 38 paternal 2555∆T mutation and the novel maternal 2670G>A mutation were found in fibroblasts from the parent of origin as well as in the twins' fibroblasts, lymphoblasts, and whole blood DNA. In contrast, a third sequence change was detected distinctively in lymphoblast and peripheral blood DNA from both twins.
This secondary alteration, in exon 30, was a 2927G>A nucleotide change, resulting in a glutamate to lysine change at amino acid 966 (E966K). By sequencing of RT-PCR products, this mutation was found to be in cis with the maternal exon 28 mutation (data not shown). The summary of these findings, confirmed by allele specific restriction digests, can be found in Figure 1 . only.
Constitutive expression of patient derived alleles
In order to test the functional properties of the alleles found, they were engineered into the pMMPpuroFANCA retroviral vector, and the corresponding retroviral supernatants were used to infect FANCA-null GM6914 cells. Transduced GM6914 cell lines were tested both by growth assay and by colony forming ability assay for mitomycin C sensitivity. This demonstrated a clearly mutant phenotype for the paternal allele (2555ΔT), whereas the maternal allele, containing the exon 28 mutation 
Cellular localization by immunofluorescence
As nuclear localization of FANCA protein is known to be required for function 31, 39 , the cellular localization of each of the mutants was studied. GM6914 cell lines infected with site-directed mutagenesis pMMPpuroFANCA-derived constructs were assayed for protein localization by immunofluorescence ( Figure 3 ). As expected, wild type FANCA was largely nuclear, but FANCA protein with the R880Q mutation localized mostly to the cytoplasm, indicating that not much FANCA was required to enter the nucleus for functional correction to occur. FANCA protein carrying either an E966K mutation or the R880Q+E966K double mutation localized mostly to the nucleus. Hence, the initial maternal mutation negatively affected sub-cellular localization of FANCA protein, and the acquired downstream mutation corrected this mis-localization. As these findings were observed in cell lines with overexpression-prone constructs, the erroneous localization of the mutant may not be the only reason for the mutant phenotype; protein and mRNA stability may also play a role at endogenous expression levels. Immunofluorescence in GM6914 cells retrovirally infected with constitutively expressed site-directed mutagenesis constructs. The R880Q mutation, but not the E966K mutation, prevents nuclear localization; both mutations in cis restore nuclear localization.
Doxycyclin regulated expression of patient derived constructs
It was hypothesized that the intermediate phenotype of the maternal allele displayed in Figure 2 might be due to constitutive, high-level expression, common to retroviral vectors, which would mask a mutation that resulted in reduced function (hypomorph). This possibility was supported by the immunofluorescence data, which clearly indicated a mutant phenotype for the maternal allele.
To test this hypothesis, the patient derived alleles of FANCA were transferred into the tetracyclin repressible pREV-TRE vector (BD Biosciences), and the pREV-TRE-FANCA constructs, containing wild type, maternal, paternal, or lymphoblast FANCA allele, were used to make retroviruses. GM6914 cells were made to express tetracyclin / doxycyclin (Dox) repressed transcription activator (tTA) via transfection with pREV-TetOff (BD Biosciences), and the three transfected clones that expressed the highest levels of tTA (clones D3, E1 and I15) were infected with the four pREV-TRE-FANCA retroviruses, each bearing a different FANCA allele. FANCA expression was determined to be Dox regulateable in the four cell lines derived from clone D3 by Western blot; only.
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Secondary mutation acquired in HSC, which repopulated the blood
Since the acquired mutation was found in peripheral blood from both twins, and since these twins were over two decades of age, it seemed likely that the secondary mutation occurred in a hematopoietic stem cell, leading to repopulation of the blood. This hypothesis was tested by confirming multilineage clonal hematopoiesis using Xinactivation assays and committed progenitor assays. First, an assay for X-inactivation skewing was undertaken using genomic DNA extracted from fibroblasts and whole blood of both twins. One twin exhibited a greater degree of skewing of X-inactivation in fibroblasts than the other twin, a phenomenon that has been previously reported in monozygotic twins [40] [41] [42] [43] [44] [45] [46] [47] . More importantly, the assay demonstrated concordant extreme skewing in the whole blood ( Figure 6 ). Specifically, one twin showed skewing of X-inactivation in opposite directions in her blood versus her skin, and X-inactivation in her blood was skewed in the same direction as it was for her sister's blood. This finding suggests that she was repopulated by a hematopoietic precursor cell from her twin sister 44 , presumably with the hematopoietic progenitor or stem cell containing the acquired mutation.
Figure 6: Skewing of X chromosome inactivation
Products from PCR with Hpa II digested and mock digested templates. Order of lanes:
100 bp ladder; then, paired, PCRs of digested and mock-digested DNA from: fibroblasts from one twin, whole blood from that twin, fibroblasts from second twin, whole blood from second twin, and fibroblasts from mother; then, as controls, Hpa II digested and mock digested male DNA as digestion controls, Hpa II "digested" TE, and Hpa II digested female DNA as non-skewed control.
Next, bone marrow was obtained from both sisters, and granulocyte-macrophage colony forming units (CFU-GM) and erythrocyte burst forming units (BFU-E) were plucked and analyzed for presence of the acquired mutation. The acquired mutation was present in 100% of colonies evaluated (180 CFU-GM and 211 BFU-E from one twin, 99
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From CFU-GM and 96 BFU-E from the other twin). Along with the finding of the acquired mutation in whole blood and in cultured lymphoblasts, this result validates the notion that a multilineage bone-marrow derived hematopoietic progenitor, probably an HSC, acquired the 2927G>A compensatory mutation.
When CFU-GM and BFU-E from both twins were tested for MMC sensitivity, both cell types from both twins demonstrated dose response curves similar to those for wild type CFU-GM and BFU-E, respectively (Figure 7 ). This indicated normal MMC resistance, and therefore functional correction of bone marrow derived committed hematopoietic prognitor cells in both patients, implying correction of bone marrow HSCs. In addition, the karyotype for bone marrow from both twins was normal (46 X,X) in 100% of metaphases examined (data not shown). For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From unassisted oligoclonal hematopoiesis over such a long time period in humans. Our findings powerfully confirm the substantial capacity of human HSC to self-renew.
Regarding the potential for gene therapy in FA, this case of "natural gene therapy" suggests that genetically corrected HSC can prevent/correct the hematological abnormalities characteristic of this disease. Here, the functionally normal HSC was spontaneously selected to become the dominant clone without the use of any exogenous myeloablative stress. Therefore, correction of only very few long-term repopulating HSC could be sufficient to have significant therapeutic benefit given sufficient time. The time required for successful in vivo selection of normal HSC is not known but it is noteworthy that one of the twins was reported to have some cells with abnormal chromosome breakage at 6 months of age. Spontaneous selection may therefore be a slow process taking years. However, gentle, non-myeloablative selection of corrected HSC has been reported in murine gene therapy for Fancc 16 and could potentially be used to safely accelerate the selection process, so long as the corrected cells are introduced prior to onset of hematological symptoms, including anemia, pancytopenia, or clonal karyotypic abnormality 14 . Based on the data presented in this paper, once the appropriate conditions for safe selection are established, very limited numbers of HSC should be capable of repopulating the bone marrow and blood of an affected FA patient as well as any histocompatible siblings via serial stem cell transplantation.
